An appraisal of antigen identification and IgG effector functions driving host immune responses in multiple sclerosis.

[1]  T. Vollmer,et al.  Aberrant Immunoglobulin G Glycosylation in Multiple Sclerosis , 2021, Journal of Neuroimmune Pharmacology.

[2]  A. Kermode,et al.  FcγRIIb Expression Is Decreased on Naive and Marginal Zone-Like B Cells From Females With Multiple Sclerosis , 2021, Frontiers in Immunology.

[3]  M. Benatar,et al.  Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis , 2020, Neurology.

[4]  P. Kennedy,et al.  The Role of Antibodies in the Pathogenesis of Multiple Sclerosis , 2020, Frontiers in Neurology.

[5]  X. Montalban,et al.  Role of B Cells in Multiple Sclerosis and Related Disorders , 2020, Annals of neurology.

[6]  S. Hauser,et al.  Treatment of Multiple Sclerosis: A Review. , 2020, The American journal of medicine.

[7]  P. Kennedy,et al.  Recombinant antibodies derived from laser captured single plasma cells of multiple sclerosis brain identified phage peptides which may be used as tools for characterizing intrathecal IgG response , 2020, Journal of Neuroimmunology.

[8]  T. Vollmer,et al.  Oligoclonal IgG antibodies in multiple sclerosis target patient-specific peptides , 2020, PloS one.

[9]  A. Kermode,et al.  IgG3 + B cells are associated with the development of multiple sclerosis , 2020, Clinical & translational immunology.

[10]  D. Booth,et al.  Higher Serum Immunoglobulin G3 Levels May Predict the Development of Multiple Sclerosis in Individuals With Clinically Isolated Syndrome , 2018, Front. Immunol..

[11]  Fleur S. van de Bovenkamp,et al.  Variable Domain N-Linked Glycans Acquired During Antigen-Specific Immune Responses Can Contribute to Immunoglobulin G Antibody Stability , 2018, Front. Immunol..

[12]  À. Rovira,et al.  The value of oligoclonal bands in the multiple sclerosis diagnostic criteria , 2018, Brain : a journal of neurology.

[13]  David H. Miller,et al.  Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria , 2017, The Lancet Neurology.

[14]  T. Vollmer,et al.  The complex relationship between oligoclonal bands, lymphocytes in the cerebrospinal fluid, and immunoglobulin G antibodies in multiple sclerosis: Indication of serum contribution , 2017, PloS one.

[15]  R. Reynolds,et al.  Complement is activated in progressive multiple sclerosis cortical grey matter lesions , 2016, Journal of Neuroinflammation.

[16]  T. Olsson,et al.  Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins , 2016, Proceedings of the National Academy of Sciences.

[17]  A. Goris,et al.  Genetic variants are major determinants of CSF antibody levels in multiple sclerosis. , 2015, Brain : a journal of neurology.

[18]  B. Lie,et al.  Oligoclonal band phenotypes in MS differ in their HLA class II association, while specific KIR ligands at HLA class I show association to MS in general , 2014, Journal of Neuroimmunology.

[19]  G. Vidarsson,et al.  IgG-effector functions: "the good, the bad and the ugly". , 2014, Immunology letters.

[20]  G. Ingram,et al.  Complement activation in multiple sclerosis plaques: an immunohistochemical analysis , 2014, Acta Neuropathologica Communications.

[21]  H. Harbo,et al.  Oligoclonal bands and age at onset correlate with genetic risk score in multiple sclerosis , 2014, Multiple sclerosis.

[22]  S. Hauser,et al.  Multiple sclerosis: Prospects and promise , 2013, Annals of neurology.

[23]  John D. Lambris,et al.  Complement in Immune and Inflammatory Disorders: Pathophysiological Mechanisms , 2013, The Journal of Immunology.

[24]  Christian Gieger,et al.  Genetic variants in the immunoglobulin heavy chain locus are associated with the IgG index in multiple sclerosis , 2013, Annals of neurology.

[25]  N. Scarmeas,et al.  The good, bad, and ugly? , 2012, Neurology.

[26]  D. Gilden,et al.  Intrathecally synthesized IgG in multiple sclerosis cerebrospinal fluid recognizes identical epitopes over time , 2011, Journal of Neuroimmunology.

[27]  Gordon F Heidkamp,et al.  Fcγ receptor IIB (FcγRIIB) maintains humoral tolerance in the human immune system in vivo , 2011, Proceedings of the National Academy of Sciences.

[28]  B. Erickson,et al.  Beneficial plasma exchange response in central nervous system inflammatory demyelination. , 2011, Archives of neurology.

[29]  T. Tiller,et al.  Development of self-reactive germinal center B cells and plasma cells in autoimmune FcγRIIB-deficient mice , 2010, The Journal of experimental medicine.

[30]  P. Calabresi,et al.  Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trial , 2009, Annals of neurology.

[31]  D. Hafler,et al.  Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid , 2009, Annals of neurology.

[32]  P. Bruhns,et al.  Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. , 2009, Blood.

[33]  A. Compston,et al.  Multiple sclerosis , 2008, The Lancet.

[34]  Y Ben-Shlomo,et al.  CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patients , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[35]  Kenneth G. C. Smith,et al.  Distinct cell-specific control of autoimmunity and infection by FcγRIIb , 2008, The Journal of experimental medicine.

[36]  D. Arnold,et al.  B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. , 2008, The New England journal of medicine.

[37]  L. Bö,et al.  Homogeneity of active demyelinating lesions in established multiple sclerosis , 2008, Annals of neurology.

[38]  J. Bennett,et al.  VH4 Gene Segments Dominate the Intrathecal Humoral Immune Response in Multiple Sclerosis1 , 2007, The Journal of Immunology.

[39]  Kenneth G. C. Smith,et al.  FcγRIIb controls bone marrow plasma cell persistence and apoptosis , 2007, Nature Immunology.

[40]  M. Carroll,et al.  Follicular exclusion of autoreactive B cells requires FcγRIIb , 2007 .

[41]  W. L. Benedict,et al.  Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.

[42]  G. Cutter,et al.  Infectious causes of multiple sclerosis , 2006, The Lancet Neurology.

[43]  J. Ravetch,et al.  Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation , 2006, Science.

[44]  H. Yagi,et al.  Differential glycosylation of polyclonal IgG, IgG-Fc and IgG-Fab isolated from the sera of patients with ANCA-associated systemic vasculitis. , 2006, Biochimica et biophysica acta.

[45]  D. Gilden,et al.  Specificity of recombinant antibodies generated from multiple sclerosis cerebrospinal fluid probed with a random peptide library , 2006, Journal of Neuroimmunology.

[46]  J. Ravetch,et al.  Divergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding , 2005, Science.

[47]  N. Tsuchiya,et al.  Role of Fcγ receptor IIb polymorphism in the genetic background of systemic lupus erythematosus: Insights from Asia , 2005, Autoimmunity.

[48]  A. Cappione,et al.  Lupus IgG VH4.34 Antibodies Bind to a 220-kDa Glycoform of CD45/B220 on the Surface of Human B Lymphocytes1 , 2004, The Journal of Immunology.

[49]  M. Sharief,et al.  Expression of CD5 on B lymphocytes correlates with disease activity in patients with multiple sclerosis , 2002, Journal of Neuroimmunology.

[50]  T. Takai.  Roles of Fc receptors in autoimmunity , 2002, Nature Reviews Immunology.

[51]  B. Weinshenker,et al.  Plasma exchange for severe attacks of CNS demyelination: Predictors of response , 2002, Neurology.

[52]  A. Matsumoto,et al.  Autoantibody activity of IgG rheumatoid factor increases with decreasing levels of galactosylation and sialylation. , 2000, Journal of biochemistry.

[53]  J. Bussel.  Fc receptor blockade and immune thrombocytopenic purpura. , 2000, Seminars in hematology.

[54]  J. Parisi,et al.  Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination , 2000, Annals of neurology.

[55]  S. Hauser,et al.  Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: A case for antigen‐specific antibody mediation , 1999, Annals of neurology.

[56]  S. Hauser,et al.  Identification of autoantibodies associated with myelin damage in multiple sclerosis , 1999, Nature Medicine.

[57]  H. Lassmann,et al.  Multiple sclerosis: In situ evidence for antibody‐ and complement‐mediated demyelination , 1998, Annals of neurology.

[58]  D. Gilden,et al.  Restricted use of VH4 Germline segments in an acute multiple sclerosis brain , 1998, Annals of neurology.

[59]  W. Ollier,et al.  The human immunoglobulin V(H) gene repertoire is genetically controlled and unaltered by chronic autoimmune stimulation. , 1996, The Journal of clinical investigation.

[60]  D R Burton,et al.  Determinants of polyreactivity in a large panel of recombinant human antibodies from HIV-1 infection. , 1996, Journal of immunology.

[61]  M. Ono,et al.  Augmented humoral and anaphylactic responses in FcγRII-deficient mice , 1996, Nature.

[62]  E. Vamvakas,et al.  The differentiation of delayed hemolytic and delayed serologic transfusion reactions: incidence and predictors of hemolysis , 1995, Transfusion.

[63]  R. Dwek,et al.  Agalactosyl glycoforms of IgG autoantibodies are pathogenic. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[64]  J. Antel,et al.  Reactive microglia in multiple sclerosis lesions have an increased expression of receptors for the Fc part of IgG , 1994, Journal of the Neurological Sciences.

[65]  Y. Masuho,et al.  Sequence analyses of three immunoglobulin G anti-virus antibodies reveal their utilization of autoantibody-related immunoglobulin Vh genes, but not V lambda genes. , 1992, The Journal of clinical investigation.

[66]  V. Pascual,et al.  The complete nucleotide sequences of the heavy chain variable regions of six monospecific rheumatoid factors derived from Epstein-Barr virus-transformed B cells isolated from the synovial tissue of patients with rheumatoid arthritis. Further evidence that some autoantibodies are unmutated copies of , 1990, The Journal of clinical investigation.

[67]  J. Y. Wang,et al.  Preferential utilization of conserved immunoglobulin heavy chain variable gene segments during human fetal life. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[68]  M. Milili,et al.  Rapid expansion of human immunoglobulin repertoire (VH, V kappa, V lambda) expressed in early fetal bone marrow. , 1990, The New biologist.

[69]  H. Wiśniewski,et al.  Identification of IgG subclasses' oligoclonal bands in multiple sclerosis CSF , 1990, Acta neurologica Scandinavica.

[70]  P. Casali,et al.  CD5+ B lymphocytes, polyreactive antibodies and the human B-cell repertoire. , 1989, Immunology today.

[71]  Pojen P. Chen,et al.  Developmentally restricted immunoglobulin heavy chain variable region gene expressed at high frequency in chronic lymphocytic leukemia. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[72]  P. Mehta,et al.  Immunoglobulin G subclass antibodies to measles virus in patients with subacute sclerosing panencephalitis or multiple sclerosis , 1989, Journal of clinical microbiology.

[73]  H. Sacks,et al.  Quantitative cerebrospinal fluid IgG measurements as a marker of disease activity in multiple sclerosis. , 1986, Archives of neurology.

[74]  W. Tourtellotte,et al.  Temporal invariance and clonal uniformity of brain and cerebrospinal IgG, IgA, and IgM in multiple sclerosis , 1986, The Journal of experimental medicine.

[75]  D. Mattson,et al.  Oligoclonal IgG in multiple sclerosis and subacute sclerosing panencephalitis brains , 1982, Journal of Neuroimmunology.

[76]  D. Mattson,et al.  Isoelectric focusing of IgG eluted from multiple sclerosis and subacute sclerosing panencephalitis brains , 1980, Nature.

[77]  R. Lisak,et al.  A search for antibodies against glial cells in the serum and cerebrospinal fluid of patients with multiple sclerosis and Guillain-Barré syndrome , 1979, Journal of the Neurological Sciences.

[78]  C. Raine,et al.  Oligodendrocyte staining by multiple sclerosis serum is nonspecific , 1979, Annals of neurology.

[79]  D. Silberberg,et al.  Antibodies to oligodendroglia in patients with multiple sclerosis. , 1977, The New England journal of medicine.

[80]  R. Dodel,et al.  IgG Fc N-glycosylation: Alterations in neurologic diseases and potential therapeutic target? , 2019, Journal of autoimmunity.

[81]  P. Youinou,et al.  CD5 expression in B cells from patients with systemic lupus erythematosus. , 2011, Critical reviews in immunology.

[82]  J. Ravetch,et al.  Fcγ receptors as regulators of immune responses , 2008, Nature Reviews Immunology.

[83]  P. Bruhns,et al.  Specificity and affinity of human Fcγ Receptors and their polymorphic variants for human IgG subclasses Running title: Fcγ Receptor selectivity for human IgG subclasses , 2008 .

[84]  J. Ravetch,et al.  The inhibitory Fcγ receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells , 2005, Nature Immunology.

[85]  M. S. Enayat,et al.  Restriction fragment length polymorphism. , 2002, Methods in molecular biology.

[86]  B. Weinshenker.  Plasma exchange for severe attacks of inflammatory demyelinating diseases of the central nervous system , 2001, Journal of clinical apheresis.

[87]  L. Cavalli-Sforza,et al.  Susceptibility to multiple sclerosis associated with an immunoglobulin gamma 3 restriction fragment length polymorphism. , 1987, The Journal of clinical investigation.